1. Landquart, January, 2016
The MedTech start-up company Swisstom AG is part of a
consortium awarded a project to develop a lung monitor for
premature babies. Thanks to direct financial support by the
Swiss Federal Government, Swisstom can participate in this
ground-breaking European project (CRADL).
Direct monitoring of lung and heart function in living humans is a vision long
sought after. Swisstom’s breakthrough technology makes this vision come true
– without using x-rays. The fundamental technology is called Electrical Impe-
dance Tomography (EIT) which Swisstom was able to develop into a marketable
product within the past four years. The first generation of Swisstom´s EIT devices
has been approved for use in adults a year ago and is now installed in selected
European clinics. In principle, the technology would be ideal for premature
babies and infants because it is completely radiation-free. However, the techno-
logy is not ready for these very small patients, yet.
Top-class consortium
Under the leadership of the worldwide renowned EIT scientist Prof. Richard
Bayford, a consortium of 11 institutes and service providers – including the
Hôpital Universitaire Genève (HUG) – received the award and funding to deve-
lop EIT for neonates with the highest acclaims for excellence by the Euro2020
experts. Swisstom is the sole implementation partner in the consortium and thus
this project is of immense importance to the start-up company in Landquart.
p ress release Ja n u a ry, 2 0 1 6
January 2016 EN © Swisstom AG 2016
Real-time tomographic images for organ
function monitoring and diagnosis
electrical
impedance
tomography
European Horizon 2020
project for neonates awarded
to Swiss start-up Swisstom
This project has received
funding from the European
Union‘s Horizon 2020 research
and innovation programme
under grant agreement
No 668259
®

2. January 2016 EN © Swisstom AG 2016
Real-time tomographic images for organ
function monitoring and diagnosis
electrical
impedance
tomography
With the provided means and partners to interact with, Swisstom has now
the resources to expand the range of application to neonates and to expand
its technological lead.
Funding despite Switzerland’s status as a “third country”
After accepting the initiative of mass immigration in the referendum of
February 9, 2014, in Switzerland, the European Union was no longer willing
to financially support Swiss research in the framework of European projects.
The Swiss State Secretary for Education, Research and Innovation SBFI closed
this financial gap and thus enables Swiss enterprises to still participate in
Horizon 2020 projects. Thanks to this medium term action, Swisstom benefits
from this exceptional opportunity. Horizon 2020 is the financial instrument
implementing the Innovation Union, a Europe 2020 flagship initiative aimed
at securing Europe‘s global competitiveness.
p ress release Ja n u a ry, 2 0 1 6
marken-startup.de15022016Concept&Design:marken-startup.de;Photo:P.RimensbergerandO.Karam,HUGGenf
Made in Switzerland
Press contact Swisstom AG
Dr. Stephan H. Böhm
Chief Medical Officer
call: +41 (0)81 330 09 72
mobile: +41 (0)79 427 74 04
mail: shb@swisstom.com
www.swisstom.com
Swisstom AG
Swisstom AG, located in Landquart, Switzerland, deve-
lops and manufactures innovative medical devices. Our
new lung function monitor enables life-saving treat-
ments for patients in intensive care and during general
anesthesia.
Unlike traditional tomography, Swisstom´s bedside
imaging is based on non-radiating principles: Electrical
Impedance Tomography (EIT). To date, no comparable
devices can show such regional organ function conti-
nuously and in real-time at the patient’s bedside.
Swisstom creates its competitive edge by passionate
leadership in non-invasive tomography with the goal to
improve individual lives and therapies.
CERTIFIED
TÜV AUSTRIA SERVICES GMBH
93/42/EEC
CERTIFICATE NO. Q112
®